000963 Huadong Medicine
- 32.94
- -0.03-0.09%
Huadong Medicine News
Deep* Company* Huadong Pharmaceutical (000963): Medical and aesthetic business is growing steadily, and multiple pipelines in the pharmaceutical industry have reached important points
The company achieved operating income of 10.411 billion yuan (+2.93%) in 2024Q1 and realized net profit of 862 million yuan (+14.18%) to mother. Many important pipelines in the company's pharmaceutical industry have reached important milestones, medical
East China Pharmaceutical (000963): 1Q24 results are in line with expectations, and the medical aesthetic and industrial microbiology sectors have maintained rapid development
Net profit for the first quarter of 2024 is in line with our expectations Huadong Pharmaceutical announced 1Q24 results: operating income of 10.411 billion yuan, up 2.93% year on year; net profit attributable to parent company was 862 million yuan, up 14 percent year on year.
Huadong Pharmaceutical (000963): Steady performance growth pipeline gradually progresses
Guide to this report: The business is growing steadily, and the innovation pipeline is expected to be realized one after another. We are optimistic about long-term growth space and maintain the rating of increasing holdings. Key investment points: Maintain an increase in holdings rating. 2024Q1 revenue of 10.411 billion yuan (+2.93%), net return to mother
Shanghai Securities released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the pharmaceutical business is growing steadily, and the medical and aesthe
Shanghai Securities released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the pharmaceutical business is growing steadily, and the medical and aesthetic trend is maintaining a good trend; 2) the company's overall operation in East China continues to grow steadily; 3) profitability has improved year-on-year; 4) actively promoting the registration and implementation of key medical and aesthetic products and expecting more products to be approved for domestic listing; 5) ATGC and Chongqing Yuyan Company have made significant progress in developing innovative botulinum toxin products. (Mainichi Keizai Shimbun)
China Galaxy released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a recommended rating. The main reasons for the rating include: 1) the main business segments are growing steadily, and the pharmaceutical busines
China Galaxy released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a recommended rating. The main reasons for the rating include: 1) the main business segments are growing steadily, and the pharmaceutical business and overseas medicine and aesthetics are under pressure in the short term; 2) R&D in the pharmaceutical industry is progressing smoothly, and several products have reached important points; 3) registration of key medical and aesthetic products has been accepted, and the product matrix is getting richer. (Mainichi Keizai Shimbun)
Huadong Pharmaceutical (000963) 2024 Quarterly Report Review: Steady performance growth pipeline gradually progresses
Guide to this report: The business is growing steadily, and the innovation pipeline is expected to be realized one after another. We are optimistic about long-term growth space and maintain the rating of increasing holdings. Key investment points: Maintain an increase in holdings rating. 2024Q1 revenue of 10.411 billion yuan (+2.93%), returned to mother
East China Pharmaceutical (000963): Medical and aesthetic business maintains high growth, innovation, transformation and continuous implementation
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 40.62 billion yuan, an increase of 7.7% over the previous year; net profit to mother was 2.84 billion yuan, an increase of 13.6% over the previous year; deducted from the country
SDIC Securities released a research report on April 26 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the continuous development of various businesses and the steady growth of 2024Q
SDIC Securities released a research report on April 26 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the continuous development of various businesses and the steady growth of 2024Q1's performance; 2) implementing domestic and international dual cycle development strategies to promote rapid development of the medical and aesthetic business; 3) continuing to enrich the layout of the innovation pipeline, and the company is expected to enter the R&D harvest period. (Mainichi Keizai Shimbun)
Huadong Pharmaceutical (000963): Achieved a good start in the first quarter, R&D progress accelerated
Performance Overview On April 25, 2024, the company released its report for the first quarter of 2024. In the first quarter of 2024, the company achieved operating income of 10.411 billion yuan, an increase of 2.93% over the previous year; achieved net profit to mother8
East China Pharmaceutical (000963): Q1 Xinckley Aesthetics +23% Continued to monitor the approval progress of the follow-up injection & energy source pipeline
Incident: The company released its 2024 quarterly report. In 24Q1, the company achieved revenue of 10.411 billion yuan/yoy +2.9%, net profit attributable to mother of 862 million yuan/yoy +14.2%, after deducting net profit of 8 million yuan.
Huadong Pharmaceutical (000963): Performance growth is steady, and new products are progressing smoothly
Incident: On April 25, 2024, the company released its report for the first quarter of 2024. 2024Q1 achieved operating income of 10.411 billion yuan, an increase of 2.93% over the previous year; net profit to mother was 862 million yuan
Express News | Huadong Pharmaceutical: Net profit for the first quarter was 862 million yuan, up 14.18% year on year
Huadong Pharmaceutical (000963.SZ)'s net profit in the first quarter increased by 14.18% to 862 million yuan. The overall operations of the core subsidiaries in China and the US continued to maintain a steady growth trend
Gelonghui, April 25 | Huadong Pharmaceutical (000963.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 10.411 billion yuan, up 2.93% year on year; realized net profit of 862 million yuan, up 14.18% year on year; realized net profit to mother after deducting non-recurring profit and loss of 838 million yuan, an increase of 10.66% year on year; both operating income and net profit achieved positive growth over the fourth quarter of 2023. For example, after deducting equity incentive expenses and profits and losses attributable to shareholders of a listed company during the reporting period, non-recurring profits and losses attributable to shareholders of a listed company can be deducted
Express News | Huadong Pharmaceutical: A wholly-owned subsidiary received a notice of acceptance of the medical device registration application
Huadong Pharmaceutical (000963): 1Q24 revenue and profit increased steadily
1Q24's revenue and profit grew steadily, maintaining the buy-rating company's quarterly report for the year 24 released on April 25. 1Q24 achieved revenue of 10.41 billion yuan (+2.9% yoy), and net profit of 860 million yuan to mother (+
East China Pharmaceutical (000963): Medical and aesthetic business is growing rapidly, product innovation continues to be implemented
The incident described the company disclosed its 2023 annual report. In 2023, the company achieved annual revenue of 40.624 billion yuan, an increase of 7.71% over the previous year, and achieved net profit attributable to shareholders of listed companies of 2,839 billion yuan, an increase over the previous year
Huadong Pharmaceutical Weight-Loss Circuit Brings Another New GLP-1/GIP Dual Target Drug Was Clinically Approved in the US
① Tonight, Huadong Pharmaceutical announced that its new GLP-1/GIP dual-target drug HDM1005 injection has been clinically approved in the US, and Huadong Pharmaceutical is further expanding its pipeline layout in the weight loss market; ② Experts believe that Huadong Pharmaceutical may not have an advantage in the competition between Simei's first biosimilar and GLP-1 dual-target new drug, but its differentiated, fast and slow combination layout is expected to lay a strong foundation for future market competition.
Huadong Pharmaceutical (000963): Performance is in line with expectations, new products are expected to enter the commercialization stage
The 2023 results are in line with our expectations. The company announced the 2023 results: 2023 operating income of 40.624 billion yuan, up 7.71% year on year; net profit to mother of 2,839 billion yuan, up 13.59 percent year on year
Huadong Pharmaceutical (000963.SZ): The HDM1005 injectable drug clinical trial application declared by China and the US East China has been approved by the US FDA
Gelonghui, April 22丨Huadong Pharmaceutical (000963.SZ) announced that recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of Huadong Pharmaceutical Co., Ltd., received a notice from the US Food and Drug Administration (“US FDA”) that the HDM1005 injectable drug clinical trial application declared by China and US East China has been approved by the US FDA to conduct phase I clinical trials in the US. HDM1005 injection is a new class 1 chemical drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and has global intellectual property rights. It is a polypeptide human GLP-1 (pancreatic hypertensive)
Express News | Huadong Pharmaceutical: HDM1005 injection, a wholly-owned subsidiary, has obtained the US FDA's approval notice for clinical trials of new drugs. The indication is weight management for adults who are overweight or obese.
Analysis
Price Target
No Data
